New trial combines HIV PrEP and STI prevention in one package for young men
NCT ID NCT07658976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to see if the tools improve PrEP use and reduce infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV PrEP (F/TDF, F/TAF, or CAB-LA) and STI PEP (doxycycline)
What this could lead to
If successful, this approach could make it easier for young men to stick with HIV prevention and reduce sexually transmitted infections.
What could go wrong
This is a Phase 3 trial, but results depend on real-world adherence and may not apply to all populations. The mHealth tools may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEXUALLY TRANSMITTED INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bronx Prevention Research Center CRS
The Bronx, New York, 10451, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundacion Huesped CRS
Buenos Aires, C1427CEA, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Pesquisa Clinicaq Evandro Chagas CRS
Manguinhos, Rio de Janeiro, 221045-900, Brazil
-
San Miguel CRS
Lima, 32-15088, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA Vine Street Clinic
Los Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••